Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics plc (NASDAQ: BCYC) is a clinical-stage pharmaceutical company developing Bicycle molecules, Bicycle Drug Conjugates (BDC) and Bicycle Radioconjugates (BRC) for oncology indications. News about BCYC often centers on progress across its clinical pipeline, strategic collaborations, and financial updates that shape the company’s development plans.
Investors and observers following BCYC news can expect regular updates on clinical trials such as the Duravelo-1 Phase 1 study, the Duravelo-2 Phase 2/3 pivotal trial in metastatic urothelial cancer, and the Duravelo-3 and Duravelo-4 Phase 1/2 studies in Nectin-4–amplified breast cancer and non-small cell lung cancer. The company also reports on data presentations at major scientific meetings, including imaging and clinical data for BRC molecules targeting EphA2 and MT1-MMP.
Company news also covers strategic partnerships, including long-term arrangements with the UK Nuclear Decommissioning Authority, the United Kingdom National Nuclear Laboratory, and SpectronRx to support an end-to-end 212Pb radiopharmaceutical supply chain. Additional announcements highlight Board of Directors changes, formation and expansion of the Research and Innovation Advisory Board, and inducement grants to new employees under the 2024 Inducement Plan.
On this BCYC news page, readers can track press releases on quarterly financial results, regulatory interactions related to zelenectide pevedotin’s potential approval pathway, and anticipated milestones such as dose selection decisions and data disclosures. For those researching Bicycle Therapeutics stock, this news feed provides a centralized view of the company’s operational, clinical, and corporate developments over time.
Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company known for its innovative bicyclic peptide (Bicycle®) technology, will be participating in three significant investor conferences in June 2024. These conferences include the Jefferies Global Healthcare Conference on June 5, the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, and the TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit on June 17. Each event will feature a live fireside chat with the company's management team.
Investors can access live webcasts of these chats through the Investor section on Bicycle Therapeutics' website, with replays available post-event.
Bicycle Therapeutics (NASDAQ: BCYC) will present emerging Phase 1/2 clinical pharmacokinetic (PK) and safety data for its Bicycle Toxin Conjugates® (BTC®) BT8009 and BT5528 at the 2024 ASCO Annual Meeting. The data show differentiated safety and tolerability profiles compared to antibody drug conjugates (ADCs). The company continues to advance its Phase 2/3 Duravelo-2 trial of BT8009, now named zelenectide pevedotin, for metastatic urothelial cancer, and BT5528 has received FDA Fast Track Designation.
Key findings include a shorter half-life for BTC molecules compared to ADCs, leading to rapid tissue penetration and potentially lower toxicities. Adverse events were reported in 84% of patients for zelenectide pevedotin and 91% for BT5528, with fewer severe side effects compared to ADCs. The full clinical data will be presented at ASCO, highlighting the potential of BTC® molecules to improve cancer patient outcomes.
Bicycle Therapeutics has announced a $555 million private placement equity financing, involving both new and existing investors.
This financing strengthens the company's balance sheet, giving it a pro forma cash position of approximately $1 billion, which extends its financial runway into the second half of 2027.
The funds will be used to advance Bicycle's pipeline of clinical-stage precision-guided therapeutics and support other research and development activities.
The financing is expected to close on May 28, 2024, subject to customary conditions.
Key investors include a U.S.-based healthcare investor, Deep Track Capital, EcoR1 Capital, Fairmount, Forbion, Perceptive Advisors, and RA Capital Management.
Bicycle Therapeutics reported recent business progress and first quarter 2024 financial results. The company showcased multiple preclinical and clinical abstracts at key industry meetings, highlighting the strength of its Bicycle® platform technology and pipeline. Key developments include the initiation of a Phase 2/3 clinical trial for BT8009 in metastatic urothelial cancer, significant progress across the R&D pipeline, and the promotion of Mike Hannay to Chief Product and Supply Chain Officer. With cash and cash equivalents of $457.0 million as of March 31, 2024, Bicycle Therapeutics is well-positioned for future growth and innovation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Bicycle Therapeutics (BCYC)?
What is the market cap of Bicycle Therapeutics (BCYC)?
